000 01261 a2200325 4500
005 20250517162055.0
264 0 _c20171016
008 201710s 0 0 eng d
022 _a2359-4292
024 7 _a10.1590/2359-3997000000267
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMaciel, Léa Maria Zanini
245 0 0 _aMedullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
_h[electronic resource]
260 _bArchives of endocrinology and metabolism
_c
300 _a398-402 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnilides
_xadverse effects
650 0 4 _aCarcinoma, Neuroendocrine
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aPiperidines
_xadverse effects
650 0 4 _aProtein Kinase Inhibitors
_xadverse effects
650 0 4 _aProto-Oncogene Mas
650 0 4 _aPyridines
_xadverse effects
650 0 4 _aQuinazolines
_xadverse effects
650 0 4 _aRisk Assessment
650 0 4 _aThyroid Neoplasms
_xdrug therapy
700 1 _aMagalhães, Patrícia Künzle Ribeiro
773 0 _tArchives of endocrinology and metabolism
_gvol. 61
_gno. 4
_gp. 398-402
856 4 0 _uhttps://doi.org/10.1590/2359-3997000000267
_zAvailable from publisher's website
999 _c27319974
_d27319974